Neuroimmunology Drugs Market worth $37.32 billion by 2030 - Exclusive Report by InsightAce Analytic

·6 min read

JERSEY CITY, N.J., July 6, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global Neuroimmunology Drugs Market By Indication (Alzheimer's disease (A.D.), Multiple Sclerosis (M.S.), Parkinson's Disease (P.D.), Myasthenia Gravis (M.G.), Neuromyelitis Optica Spectrum Disorder (NMOSD), Guillain-Barre Syndrome (GBS), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Amyotrophic Lateral Sclerosis (ALS), and Others), Product Type (Small Molecules, Monoclonal Antibodies, Recombinant Protein, and Others))- Trends, Industry Competition Analysis, Revenue and Forecast To 2030."


According to the latest research by InsightAce Analytic, global neuroimmunology drugs market is valued at US$ 20.78 billion in 2021, and it is expected to reach US$ 37.32 billion by 2030, with a CAGR of 6.93% during the forecast period of 2022-2030.

Request for Sample Pages:

Neuroimmunological disorders are diseases that appear to be caused by the immune system attacking the nervous system (central or peripheral). A neuroimmunology drug aims to regulate immune system activity to treat neurological diseases with underlying immune pathologies. For treating neurological conditions, various neuroimmunology therapeutic strategies are being researched and used, including medicines that Product different cytokine subtypes, medications that bind only to specific receptors, and drugs that affect the migration of immune cells.

In the coming forecasting period, the presence of a large number of drugs in the pipeline for the treatment of neuroimmunology diseases such as Multiple Sclerosis (M.S.) and Alzheimer's disease (A.D.) is likely to create enormous opportunities for the market. Biogen and Eisai had launched several initiatives to assist patients with Alzheimer's disease in gaining access to ADUHELMTM. It is the first new Alzheimer's treatment approved in the United States. These initiatives seek to assist patients and their families in understanding the disease, navigating the diagnostic process, obtaining culturally competent care, and affording treatment. Currently, there are almost 220 neuroimmunology drugs in Phase I, II, III, and later stages of development. The rising prevalence of neuroimmunology diseases is expected to drive significant demand for advanced treatment options worldwide.

However, the high cost of mAb-based therapy may significantly impede the market growth. However, research and development activities among research universities, hospitals, and market participants are expected to generate enormous opportunities for global market growth.

Considering the high R&D spending and rapid research on dementia, immunology diseases, and strong product pipeline, North America is expected to lead the neuroimmunology market during the forecast period, followed by Europe. Furthermore, significant funding for Alzheimer's Disease will be responsible for the growth in upcoming forecast period.

Major market players operating in the market includes F. Hoffmann-La Roche Ltd, Biogen, AstraZeneca Plc, Johnson & Johnson, Merck KGaA, Novartis AG, Sanofi, UCB SA, Eisai Co Ltd, Eli Lilly, AB Science S.A., Actelion Pharmaceuticals Ltd., AstronauTx, Alector, AZTherapies Inc., Celgene Corp., INmune Bio, Inc., Lundbeck, Genetech Inc., Grifols SA, Tiaki Therapeutics, T.G. Therapeutics Inc., AevisBio Inc., Monument Tx, ImmunoBrain Checkpoint, Talisman Therapeutics, Inflammasome Therapeutics, T3D Therapeutics, TauRX Therapeutics Ltd and among others.

Key Developments In The Market:

  • In Jan 2022, Exscientia and Sanofi announced a ground-breaking research partnership and licence agreement to create up to 15 novel small molecule candidates in the fields of immunology and oncology by utilizing Exscientia's end-to-end AI-driven platform and real patient samples.

  • In June 2021, the European Commission approved Roche's Enspryng for use in neuromyelitis optical spectrum disorder (NMOSD). Roche is trying to distinguish Enspryng from Alexion's Soliris in the E.U. by using subcutaneous administration, which could support dosing at home.

  • In Aug 2020, Johnson & Johnson will purchase Momenta Pharmaceuticals, Inc., strengthening Janssen's position as a leader in cutting-edge therapies for autoimmune diseases. Nipocalimab (M281), a clinically proven and possibly best-in-class anti-FcRn antibody, will be included in the deal with full worldwide rights. Acquisition of Momenta for $6.5 billion through an all-cash tender offer priced at $52.50 per share.

  • In Jan 2020, Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer's Disease (A.D.) and Parkinson's Disease (P.D.) from Pfizer Inc. The agreement will include a $75 million upfront payment, up to $635 million in potential future commercialization and development milestone payments, and tiered royalties ranging from the high single digits to the low teens.

Curious about this latest version of the report? Obtain Report Details @

Global Neuroimmunology Drugs Market, by By Indications, 2022-2030 (Value US$ Mn)

  • Alzheimer's disease (A.D.)

  • Multiple Sclerosis (M.S.)

  • Parkinson's Disease (P.D.)

  • Myasthenia Gravis (M.G.)

  • Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Guillain-Barre Syndrome (GBS)

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

  • Amyotrophic Lateral Sclerosis (ALS)

  • Others

Global Neuroimmunology Drugs Market, by Product Type, 2022-2030 (Value US$ Mn)

  • Small Molecules

  • Monoclonal Antibodies

  • Recombinant Protein

  • Others

Global Neuroimmunology Drugs Market, by Region, 2022-2030 (Value US$ Mn)

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

North America Neuroimmunology Drugs Market, by Country, 2022-2030 (Value US$ Mn)

  • U.S.

  • Canada

Europe Neuroimmunology Drugs Market, by Country, 2022-2030 (Value US$ Mn)

  • Germany

  • France

  • Italy

  • Spain

  • Russia

  • Rest of Europe

Asia Pacific Neuroimmunology Drugs Market, by Country, 2022-2030 (Value US$ Mn)

  • India

  • China

  • Japan

  • South Korea

  • Australia & New Zealand

Latin America Neuroimmunology Drugs Market, by Country, 2022-2030 (Value US$ Mn)

  • Brazil

  • Mexico

  • Rest of Latin America

Middle East & Africa Neuroimmunology Drugs Market, by Country, 2022-2030 (Value US$ Mn)

  • GCC Countries

  • South Africa

  • Rest of Middle East & Africa

Why should buy this report:

  • To receive a comprehensive clinical trial/pipeline product analysis of the prospects for the global neuroimmunology drugs market

  • To receive an industry overview and future trends of the neuroimmunology drugs market

  • To analyze neuroimmunology drugs market drivers and challenges

  • To get information on the neuroimmunology drugs market size (Value US$ Bn) forecast to 2030

  • To get detailed insights regarding significant investments, mergers & acquisitions in the neuroimmunology drugs market industry

For More Customization @

Other Related Reports Published by InsightAce Analytic:

Global Neuropsychiatric Drugs Market   
Global Neurodegenerative Disease Market   
Global Preclinical Oncology Models Market    
Global Immuno-Oncology Cell Therapy Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:
InsightAce Analytic Pvt. Ltd. 
Tel.: +1 551 226 6109 
Site Visit:
Follow Us on LinkedIn @
Follow Us On Facebook @



View original content:

SOURCE InsightAce Analytic Pvt. Ltd.